A hypercoagulable state leading to venous limb gangrene associated with occult lung adenocarcinoma
Authors:
- Matthew M. A. WaiteMWMatthew M. A. Waite
- Anthony W. MartinelliAMAnthony W. Martinelli
- Stephen D. PrestonSPStephen D. Preston
- Emily SymingtonESEmily Symington
- Robert C. RintoulRRRobert C. Rintoul
- Patrick CoughlinPCPatrick Coughlin
- Paul HayesPHPaul Hayes
- David GilliganDGDavid Gilligan
- Martin BesserMBMartin Besser
Open Access
- 25 March 2019
- journal article
- case report
- Published by Wiley in Clinical Case Reports
- Vol. 7 (5) , 888-892
Abstract
Key Clinical Message: We report a case of lung adenocarcinoma‐associated hypercoagulability leading to venous limb gangrene, managed successfully with argatroban and then dabigatran. Use of idarucizumab permitted diagnostic investigations, leading to targeted antineoplastic therapy with crizotinib, surgical resection with curative intent, and continued survival over 2 years after the index event.Keywords
This publication has 11 references indexed in Scilit:
- Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)Journal of Clinical Oncology, 2018
- Edoxaban for the Treatment of Cancer-Associated Venous ThromboembolismNew England Journal of Medicine, 2018
- ALK-Rearranged Non–Small-Cell Lung Cancer Is Associated With a High Rate of Venous ThromboembolismClinical Lung Cancer, 2017
- JAK2V617F and calreticulin mutations in recurrent venous thromboembolism: results from the EDITH prospective cohortAnnals of Hematology, 2016
- Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjectsEuropean Journal of Clinical Pharmacology, 2016
- The polyphosphate/factor XII pathway in cancer-associated thrombosis: novel perspectives for safe anticoagulation in patients with malignanciesThrombosis Research, 2016
- Warfarin-induced venous limb ischemia/gangrene complicating cancer: a novel and clinically distinct syndromeBlood, 2015
- Crizotinib (PF‐02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P‐glycoproteinBritish Journal of Pharmacology, 2012
- Venous Gangrene a Rare but Dreadful Complication of Deep Venous ThrombosisClinical and Applied Thrombosis/Hemostasis, 2010
- Trousseau's syndrome associated with tissue factor produced by pulmonary adenocarcinomaThorax, 2006